Bliss GVS Pharma reported its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the standalone and consolidated financial results on May 12, 2026. In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published an extract of the audited financial results in The Economic Times, The Free Press Journal, Maharashtra Times, and Navshakti on May 14, 2026. The Board recommended a final dividend of ₹1 per equity share for FY26, subject to shareholder approval at the 41st Annual General Meeting scheduled for July 15, 2026. The statutory auditors issued an unmodified opinion on the financial results.

Standalone Financial Performance

On a standalone basis, the company posted a net profit of ₹9,687.44 lakh for FY26, compared to ₹6,896.87 lakh in the previous year. Revenue from operations grew to ₹72,980.76 lakh from ₹56,720.46 lakh. For the quarter ended March 31, 2026, standalone net profit stood at ₹3,242.25 lakh, while revenue from operations rose to ₹21,153.73 lakh.

*Not Annualised

Consolidated Financial Performance

On a consolidated basis, the company reported a net profit of ₹13,472.77 lakh for FY26, compared to ₹9,025.53 lakh in FY25. Consolidated total income from operations for the full year stood at ₹1,00,064.26 lakh against ₹84,621.97 lakh in the prior year. For Q4 FY26, consolidated net profit came in at ₹3,699.87 lakh.

*Not Annualised

Key Highlights

• Standalone net profit for FY26 rose to ₹9,687.44 lakh from ₹6,896.87 lakh.
• Consolidated net profit for FY26 stood at ₹13,472.77 lakh, up from ₹9,025.53 lakh.
• Final dividend of ₹1 per equity share recommended for FY26, subject to shareholder approval.
• 41st AGM scheduled for July 15, 2026, via video conferencing.

Bliss GVS Pharma Limited has disclosed the voting results of its postal ballot conducted through a remote e-voting process, pursuant to Section 108 and Section 110 of the Companies Act, 2013, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The record date for determining eligible shareholders was April 07, 2026, on which date the total number of shareholders stood at 45,804. Two special resolutions were put to vote, both concerning the appointment of Non-Executive Independent Directors for a term of five years each.

Postal Ballot Process and Scrutinizer's Report

The Board of Directors of Bliss GVS Pharma appointed Mr. Vijay Yadav (FCS - 11990), Partner of M/s. AVS & Associates, Company Secretaries, as the Scrutinizer for the postal ballot and e-voting process via a circular resolution passed on April 03, 2026. The e-voting facility was provided by Central Depository Services (India) Limited (CDSL). The voting period commenced on Friday, April 10, 2026 (09:00 A.M. IST) and concluded on Saturday, May 09, 2026 (05:00 P.M. IST). The Scrutinizer submitted his report to the Company on May 11, 2026, and the results were disclosed on May 12, 2026.

Resolution 1: Appointment of Mr. Vijayanarayanan Mahadevan as Independent Director

The first special resolution pertained to the appointment of Mr. Vijayanarayanan Mahadevan (DIN: 06639177) as a Non-Executive Independent Director for a term of five years. The promoter and promoter group were not interested in this resolution. The detailed voting outcome is presented below:

The resolution was passed, with 99.72% of votes polled cast in favour. There were no invalid votes recorded across any shareholder category.

Resolution 2: Appointment of Mr. Deepak Rameshchandra Shah as Independent Director

The second special resolution concerned the appointment of Mr. Deepak Rameshchandra Shah (DIN: 06954206) as a Non-Executive Independent Director for a term of five years. The promoter and promoter group were not interested in this resolution either. The voting results are as follows:

This resolution was also passed, with 99.72% of votes polled cast in favour. No invalid votes were recorded in any category.

Key Highlights of the Postal Ballot

• Record Date: April 07, 2026
• Total Shareholders on Record Date: 45,804
• Voting Period: April 10, 2026 (09:00 A.M. IST) to May 09, 2026 (05:00 P.M. IST)
• E-voting Platform: Central Depository Services (India) Limited (CDSL)
• Scrutinizer: Mr. Vijay Yadav, Partner, M/s. AVS & Associates, Company Secretaries (FCS - 11990, COP No: 16806)
• Scrutinizer's Report Date: May 11, 2026
• Total Resolutions Passed: 2
• Invalid Votes: Nil across all categories for both resolutions

The voting results and the Scrutinizer's report have been uploaded on the Company's website at www.blissgvs.com . The disclosure was submitted to the National Stock Exchange of India and BSE Limited on May 12, 2026, and was signed by Aditi Bhatt, Company Secretary of Bliss GVS Pharma Limited.